US-based wound care technology company Imbed Biosciences has launched a dual-action wound matrix, SAM PainGuard with Lidocaine.
SAM PainGuard, a part of Imbed’s advanced wound care technology, is designed to offer bioburden management and pain relief in a single solution.
The new product features two brands, including Surgaflex PainGuard for surgical wounds and Pelashield PainGuard for burn and trauma wound management.
SAM PainGuard leverages Imbed’s SAM Antimicrobial technology, which combines multiple wound care agents into a single bioresorbable polymer matrix.
The Surgaflex PainGuard and Pelashield PainGuard are now available in the US, expanding Imbed’s portfolio of SAM-based solutions.
Imbed Biosciences CEO Terry Bromley said: “Nearly 90% of patients report moderate to severe pain following surgery.
“Managing this pain effectively from the start is critical—not only to reduce reliance on systemic pain medications, including opioids, but also to prevent long-term complications such as anxiety, PTSD, and delayed healing, which can be a challenge especially in burn care.”
SAM PainGuard features a dual-action, ultra-thin matrix that combines antimicrobial silver with lidocaine HCl, offering sustained microbial reduction for up to 72 hours.
Its porous, bioresorbable polymer conforms to wound micro-textures and does not require removal, reducing the risks associated with animal-derived products.
The synthetic composition ensures low levels of ionic and metallic silver, maintaining non-toxic levels while providing effective antimicrobial action.
The matrix is said to deliver acute pain relief that lasts up to three hours and is available in a ready-to-use, unit-dose format, for consistent and safe application.
The SAM PainGuard has received 510 (k) clearance from the US Food and Drug Administration (FDA), confirming its safety and efficacy.
Imbed research and development vice president Gaurav Pranami said: “These clinical challenges were the driving force behind the development of SAM PainGuard.
“By incorporating lidocaine alongside antimicrobial silver, we’ve created a matrix that addresses both bioburden and pain in a convenient, unit-dose format.”
According to Imbed, SAM PainGuard provides antimicrobial protection, along with acute pain relief, streamlining wound care processes and enhancing patient care.
The matrix delivers a controlled release of lidocaine HCl, comparable to a 4% ointment, with over 80% released in the first 30 minutes for immediate pain relief.
It can be used for various wound types, including surgical, burn, donor site, trauma, and chronic wounds, and particularly after dressing changes and debridement.
Furthermore, the product received positive feedback in the pre-launch evaluations, highlighting its effectiveness in pain management and convenience for clinical use.
Imbed Biosciences supply chain vice president Sanjay Gupta said: “We have successfully engineered and translated our unique multi-agent matrix into a clinically-relevant solution that enables uniform coverage and controlled dosing.
“With a design that simplifies clinical workflows and reduces possible side-effects by preventing uneven lidocaine applications, which can occur with gels or ointments.”
